The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMW 2019 | Are novel therapeutics replacing ASCT?
Hermann Einsele
• 14 Sep 2019
Prof. Hermann Einsele, MD, FRCP, of the University of Würzburg, Würzburg, Germany, outlines which patient populations allogeneic stem cell transplantations (ASCT) are most relevant, and whether novel therapeutics now challenge this. This interview was recorded at the International Myeloma Workshop (IMW) 2019, in Boston, MA.
